Literature DB >> 11115950

The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation.

J W Cohen Stuart1, M D Hazebergh, D Hamann, S A Otto, J C Borleffs, F Miedema, C A Boucher, R J de Boer.   

Abstract

To distinguish between antigenic stimulation and CD4+ T-cell homeostasis as the cause of T-cell hyperactivation in HIV infection, we studied T-cell activation in 47 patients before and during highly active antiretroviral therapy (HAART). We show that expression of human leukocyte antigen (HLA)-DR, CD38, and Ki67 on T cells decreased during HAART but remained elevated over normal values until week 48 of therapy. We confirm previous reports that T-cell activation correlates positively with plasma HIV RNA levels (suggesting antigenic stimulation), and negatively with CD4 count (suggesting CD4+ T-cell homeostasis). However, these correlations may be spurious, because misleading, due to the well-established negative correlation between CD4 count and plasma HIV RNA levels. To resolve this conflict, we computed partial correlation coefficients. Correcting for CD4 counts, we show that plasma HIV RNA levels contributed to T-cell hyperactivation. Correcting for plasma HIV RNA levels, we show that CD4+ T-cell depletion contributed to T-cell activation. Correcting for both, activation of CD4+ and CD8+ T cells remained positively correlated. Because this suggests that CD4+ and CD8+ T-cell activation is caused by a common additional factor, we conclude that antigenic stimulation by HIV or other (opportunistic) infections is the most parsimonious explanation for T-cell activation in HIV infection. Persistence of HIV antigens may explain why T-cell activation fails to revert to levels found in healthy individuals after 48 weeks of therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115950     DOI: 10.1097/00126334-200011010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  28 in total

1.  Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients.

Authors:  P Brazille; N Dereuddre-Bosquet; C Leport; P Clayette; O Boyer; J-L Vildé; D Dormont; O Benveniste
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

2.  Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.

Authors:  Ruy M Ribeiro; Mette D Hazenberg; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Modeling the timing of antilatency drug administration during HIV treatment.

Authors:  Janka Petravic; Alexey Martyushev; Jeanette C Reece; Stephen J Kent; Miles P Davenport
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

4.  Limited CD4+ T cell proliferation leads to preservation of CD4+ T cell counts in SIV-infected sooty mangabeys.

Authors:  Ming Liang Chan; Janka Petravic; Alexandra M Ortiz; Jessica Engram; Mirko Paiardini; Deborah Cromer; Guido Silvestri; Miles P Davenport
Journal:  Proc Biol Sci       Date:  2010-06-30       Impact factor: 5.349

5.  Th-1-type cytotoxic CD8+ T-lymphocyte responses to simian immunodeficiency virus (SIV) are a consistent feature of natural SIV infection in sooty mangabeys.

Authors:  Zichun Wang; Benjamin Metcalf; Ruy M Ribeiro; Harold McClure; Amitinder Kaur
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Activation and coreceptor expression of T lymphocytes in HIV/AIDS patients of China.

Authors:  Hong Shang; Zining Zhang; Yongjun Jiang; Xiaoxu Han; Yanan Wang; Min Zhang; Xiaohui Ye; Ying Liu; Yingying Diao; Di Dai; Wenqing Geng
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

7.  Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals.

Authors:  M Paiardini; D Galati; B Cervasi; G Cannavo; L Galluzzi; M Montroni; D Guetard; M Magnani; G Piedimonte; G Silvestri
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Quantifying T lymphocyte turnover.

Authors:  Rob J De Boer; Alan S Perelson
Journal:  J Theor Biol       Date:  2013-01-09       Impact factor: 2.691

9.  Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.

Authors:  Babafemi Taiwo; Roy M Matining; Lu Zheng; Michael M Lederman; Charles R Rinaldo; Peter S Kim; Baiba I Berzins; Daniel R Kuritzkes; Amy Jennings; Joseph J Eron; Cara C Wilson
Journal:  J Antimicrob Chemother       Date:  2013-04-18       Impact factor: 5.790

10.  Role of immune activation in CD4+ T-cell depletion in HIV-1 infected Indian patients.

Authors:  M Vajpayee; S Kaushik; V Sreenivas; K Mojumdar; S Mendiratta; N K Chauhan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-09       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.